Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1152W HIGH $99.75
Volume
5.26 M
Value Traded
100.82 K
Short % Float
124.73%
Days to Cover
1.0
+8%Week
-58.3%1 Month
-6.09%3 Month
-17.56%6 Month
-99.97%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
55.89 M
EPS (TTM)
-2.47
P/E Ratio
-
Ent. Value
48.74 M
Total Shares
51.75 M
Float Shares
1.02 M
Insiders
98.03%
Institutions
3.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SDEV Catalyst Timeline
Dated clinical, regulatory and corporate events for Stablecoin Development Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Stablecoin Development Corporation
35Total events
0Upcoming
2Tier-1 (high impact)
2011 to 2026Coverage
Event history 35
●Equity OfferingCorporate
First tranche of January 2026 Pre-Funded Warrants became exercisable
◆Quarterly UpdateCorporate
2025 annual meeting of stockholders expected in Q4 2025 to approve second closing
▼Equity OfferingCorporate
NovaBay enters $6M securities purchase agreement with investor David E. Lazar
◆Management ChangeCorporate
David E. Lazar appointed CEO and director; Justin Hall becomes VP of Business Development
◆Management ChangeCorporate
Jack McGovern joins as CFO in mid July; Tom Paulson to retire at year end
●Product LaunchPost-Market
NovaBay Hydrogel product for night-time use launch planned for late 2016, subject to FDA clearance
blepharitis, meibomian gland dysfunction, dry eyesource ↗
◆Runway Guidance UpdateCorporate
Company intends to become cash flow positive by December 2016
◆Quarterly UpdateCorporate
NovaBay expects to report Q4 and full year 2015 financial results and hold conference call in early March 2016
▲Quarterly UpdateAvenovaCorporate
NovaBay expects Q4 2015 Avenova sales to exceed $1.5 million and full year 2015 sales to approach $4 million
eye caresource ↗
◆Runway Guidance UpdateCorporate
Management affirms goal of reaching positive cash flow from operations in late 2016
●Product LaunchNovaClearPost-Market
NovaClear with intelli-Case test market launch expected in late 2015 or early 2016
contact lens disinfectionsource ↗
●Quarterly UpdateCorporate
NovaBay plans to report third quarter 2015 financial results in mid-November
▲Quarterly UpdateAvenovaCorporate
Third quarter 2015 Avenova sales expected to exceed $1 million, up ~30% over Q2 2015
blepharitis, meibomian gland dysfunction, dry eyesource ↗
▲Quarterly UpdateAvenovaCorporate
Expanding Avenova sales representatives to 50 in October 2015 from 35
blepharitis, meibomian gland dysfunction, dry eyesource ↗
▼Equity OfferingCorporate
Public offering completed in October 2015 raising $2.3 million net proceeds
▲Management ChangeCorporate
Appointment of Mark M. Sieczkarek and Dr. Massimo Radaelli to Board of Directors
▲Topline ReadoutauricloseneClinical Data
Positive top-line results from Phase 2 study of auriclosene for UCBE
urinary catheter blockage and encrustationsource ↗
▲Primary Endpoint MetauricloseneClinical Data
Primary endpoints achieved showing statistically significant reduction in encrustation and blockage
urinary catheter blockage and encrustationsource ↗
▲Management ChangeCorporate
David W. Stroman appointed Senior Vice President, Ophthalmic Drug Development
Past FDA Catalysts and PDUFA Decisions
How SDEV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SDEV program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| R01 Fund LP10% Owner | Sell | -24,720 22,668,516 held | $1.09 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SDEV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SDEV for Q2 2026. | ||||
SDEV Institutional Ownership Trends
SDEV Short Interest
Shares sold short, counted twice a month.
124.73%
Short % of Float
of tradable shares sold short
1.3M
Shares Sold Short
-63.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
47.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SDEV ranks across every disease it competes in
Competitive Position is a premium feature
See how SDEV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSDEV News
SDEVStablecoin Development Corporation Reports Third Quarter 2026 Financial Results
Stablecoin Development Corporation (SDEV) reported strong financial results for Q3 2026, with a net income of $50.4 million driven by a significant unrealized gain on its digital assets. The company's SKY holdings increased to 2.32 billion tokens, representing 10% of the total supply. Staking revenue for the quarter was $2.1 million, reflecting the company's successful staking activities.
Read more →SDEVStablecoin Development Corporation Reports Second Quarter 2026 Financial Results
Stablecoin Development Corporation (SDEV) reported its financial results for Q2 2026, highlighting a staking revenue of $2.2 million. The company faced an operating loss of $53.8 million, primarily due to a non-cash unrealized loss on digital assets. Despite these challenges, SDEV increased its SKY token holdings to 2.29 billion, representing 10% of the total supply, and eliminated warrant liabilities to streamline its capital structure.
Read more →SDEVStablecoin Development Corporation Reports First Quarter 2026 Financial Results
Stablecoin Development Corporation reported strong financial results for Q1 2026, with an operating income of $22.3 million and a GAAP net income of $552.4 million, largely due to non-cash gains from warrant liabilities. The company held approximately 2.15 billion SKY tokens and generated $2.5 million in staking revenue. These results reflect a successful transition to an on-chain holding company focused on the stablecoin economy.
Read more →SDEVStablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”
Stablecoin Development Corporation, formerly NovaBay Pharmaceuticals, began trading on the NYSE American under the ticker SDEV on April 6, 2026. The company aims to provide public market access to the stablecoin economy, focusing on the Sky protocol ecosystem. As of March 31, 2026, it holds approximately 2.15 billion SKY tokens and has earned around 35.3 million in staking rewards.
Read more →SDEVNovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
NovaBay Pharmaceuticals announced its name change to Stablecoin Development Corporation, effective April 3, 2026. The company holds approximately 2.06 billion SKY tokens, representing 8.78% of the total supply. It has also earned about 26.6 million SKY tokens in staking rewards since starting on-chain activities. The change reflects a strategic focus on the stablecoin economy.
Read more →SDEVPharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards Calif. (October 20, 2025) - NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company")
NovaBay Pharmaceuticals, Inc. has announced its compliance with the NYSE American's continued listing standards after previously being notified of non-compliance. The company achieved this by raising funds through the sale of pre-funded warrants and preferred stock, increasing its stockholders' equity above the required minimum of $6 million. A formal notification from the NYSE American confirmed that NovaBay has resolved the earlier deficiencies. The company focuses on developing eyecare, wound care, and skin care products.
Read more →SDEVNovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
NovaBay Pharmaceuticals announced a special cash dividend of $0.80 per share, payable on September 29, 2025, to stockholders of record as of September 15, 2025. The company assured that this dividend will not impact their ability to pursue strategic transactions. An annual meeting is scheduled for October 16, 2025, where shareholders can vote on various proposals. The CEO expressed a strong optimism towards the company’s future and its ongoing strategic evaluations.
Read more →SDEVNovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share
NovaBay Pharmaceuticals has declared a one-time special cash dividend of $0.80 per share, payable on September 29, 2025, to stockholders recorded as of September 15, 2025. The dividend reflects the company's strategy to return value to its shareholders and indicates optimism about its future potential. Stockholders should be aware of trading implications during the Dividend Right Period, which runs from the record date to the payment date. The announcement also includes forward-looking statements, stressing the risks and uncertainties inherent in such projections.
Read more →SDEVNovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar Investment to support NovaBay's continued public listing and provide funding for a future strategic transaction
NovaBay Pharmaceuticals has entered into a $6 million securities purchase agreement with investor David E. Lazar to strengthen its financial position. Lazar will assume the role of CEO, succeeding Justin Hall, who will become Vice President of Business Development. This investment will allow NovaBay to avoid liquidation and continue trading on the NYSE. The company plans to pursue strategic investments or acquisitions using the funds, along with a special cash dividend expected in the third quarter of 2025.
Read more →SDEVNovaBay Pharmaceuticals Announces CFO Transition 30-year finance veteran Jack McGovern joins NovaBay in mid July, current CFO Tom Paulson to retire at year end EMERYVILLE, Calif. ( July 10 , 2017) - NovaBay Pharmaceutica
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-inf
Read more →SDEVNovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements Affirms goal of reaching positive adjusted cash flow from operations in December EMERYVILLE, Calif. (October 31 , 2016) - N
Stay informed on NovaBay's progress: Download our Mobile InvestorApp from the Apple Store or Google Play Connect with NovaBay on LinkedIn Visit NovaBay's Website For NovaBay Avenova purchasing information, please contact: Call us: 1-800-890-0329 Chief Financial Officer
Read more →SDEVNovaBay Pharmaceuticals Completes $11.8 Million Private Placement EMERYVILLE, Calif. (
Forward-Looking Statements This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the anticipated market acc
Read more →SDEVNovaBay Pharmaceuticals Appoints Todd Zavodnick to its Board of Directors Closes first tranche of $11.8 million private placement EMERYVILLE, Calif . (
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova lid and lash hygiene for the domestic eye care market. Avenova is formulated with Neutrox which is clear
Read more →SDEVNovaBay Pharmaceuticals Announces $2.83 Million Private Placement Investors include insiders Pioneer Pharma and NovaBay Chairman and Interim President and CEO Mark M. Sieczkarek
Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchang
Read more →SDEVNovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million Avenova sales up approximately 41% over the third quarter on record pharmacy- filled prescriptions and direct sales Avenova sales f
Forward-Looking Statements This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the anticipated market acc
Read more →SDEVNovaBay Pharmaceuticals Secures $3 Million Bridge Loan Backers Include NovaBay Board Members, China Pioneer Pharma and China Kington Asset Management Co. Ltd. EMERYVILLE, Calif. (
Forward-Looking Statements This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the anticipated market acc
Read more →SDEVNovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova Commercialization and Reports Third Quarter Financial Results Names Chairman Mark M. Sieczkarek Interim President and CEO Third quarter Avenova sales ex
Third Quarter and Recent Operational and Financial Highlights NovaBay reports financial results for the three and nine months ended September 30, 2015. Highlights of the third quarter of 2015 and recent weeks include: Third Quarter 2015 Financial Results NovaBay reported total
Read more →SDEVNovaBay Announces Proposed Public Offering of Common Stock and Warrants
NovaBay Announces Proposed Public Offering of Common Stock and Warrants EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the globa
Read more →SDEVNovaBay Pharmaceuticals Provides Update on Avenova Sales Growth, Reports Progress with intelli-Case Test Market Launch and Product Pipeline Advancement Third quarter Avenova sales expected to top $1 million, up about 30%
NovaBay Pharmaceuticals Provides Update on Avenova Sales Growth, Reports Progress with intelli-Case Test Market Launch and Product Pipeline Advancement Third quarter Avenova sales expected to top $1 million, up about 30% over the second quarter of 2015, with pharmacy-filled pres
Read more →SDEVNovaBay Pharmaceuticals APPOINTS MARK M. SIECZKAREK, SOLTA MEDICAL CHAIRMAN AND CEO AND DR. MASSIMO RADAELLI, NOVENTIA PHARMA CEO TO ITS BOARD OF DIRECTORS Combined total of over 50 Years of Healthcare Experience in Glob
NovaBay Pharmaceuticals APPOINTS MARK M. SIECZKAREK, SOLTA MEDICAL CHAIRMAN AND CEO AND DR. MASSIMO RADAELLI, NOVENTIA PHARMA CEO TO ITS BOARD OF DIRECTORS Combined total of over 50 Years of Healthcare Experience in Global Markets Adds Significant Depth to NovaBay's Board EMERY
Read more →About Stablecoin Development Corporation
Headquarters222 LAKEVIEW AVE, SUITE 800, WEST PALM BEACH, FL, 33401
BIOPHARMAWATCH ELITE PLUS
Trade the next SDEV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime